AstraZeneca Rejects Pfizer’s Latest $119B Offer

The board of directors of British drug maker AstraZeneca Plc has rejected the raised $119 billion takeover bid from U.S. drugmaker Pfizer (PFE). In a statement released Monday, AstraZeneca’s board said that Pfizer’s latest offer of £55.00 ($95.52) per share undervalues the company, and the 15% increase constituted only a minor improvement over the company’s […] View the full post at: AstraZeneca Rejects Pfizer’s Latest $119B Offer Related posts: Cramer Likes the BB&T Secondary Offer, Again Standard & Poor’s Cuts CIT Rating Consumer Confidence Slumps To Record Low… Finally!